Activation of a new miRNAs-phospho-STAT3 pathway that is involved in the development of hepatic steatosis may represent a target for novel therapeutic strategies and might also have potential as a biomarker for diagnosis. This evidence concerns the gene STAT3 and fatty liver disease.